Grillo Mark P, Lohr Michelle Tadano
Pharmacokinetics and Drug Metabolism, Amgen Inc., South San Francisco, CA 94080, USA.
Drug Metab Dispos. 2009 May;37(5):1073-82. doi: 10.1124/dmd.108.026153. Epub 2009 Feb 5.
Phenylacetic acid (PAA) represents a substructure of a class of nonsteroidal anti-inflammatory carboxylic acid-containing drugs capable of undergoing metabolic activation in the liver to acylcoenzyme A (CoA)- and/or acyl glucuronide-linked metabolites that are proposed to be associated with the formation of immunogenic, and hence potentially hepatotoxic, drug-protein adducts. Herein, we investigated the ability of PAA to undergo phenylacetyl-S-acyl-CoA thioester (PA-CoA)-mediated covalent binding to protein in incubations with freshly isolated rat hepatocytes in suspension. Thus, when hepatocytes were incubated with phenylacetic acid carboxy-(14)C (100 microM) and analyzed for PA-CoA formation and covalent binding of PAA to protein and over a 3-h time period, both PA-CoA formation and covalent binding to protein increased rapidly, reaching 1.3 microM and 291 pmol equivalents/mg protein after 4 and 6 min of incubation, respectively. However, the covalent binding of PAA to protein was reversible and decreased by 72% at the 3-h time point. After 3 h of incubation, PAA was shown to be metabolized primarily to phenylacetyl-glycine amide (84%). No PAA-acyl glucuronide was detected in the incubation extracts. PA-CoA reacted readily with glutathione in buffer, forming PA-S-acyl-glutathione; however, this glutathione conjugate was not detected in hepatocyte incubation extracts. Coincubation of hepatocytes with lauric acid led to a marked inhibition of PA-CoA formation and a corresponding inhibition of covalent binding to protein. SDS-polyacrylamide gel electrophoresis analysis showed the formation of two protein adducts having molecular masses of approximately 29 and approximately 33 kDa. In summary, PA-CoA formation in rat hepatocytes leads to the highly selective, but reversible, covalent binding to hepatocyte proteins, but not to the transacylation of glutathione.
苯乙酸(PAA)是一类含非甾体抗炎羧酸药物的亚结构,这类药物能够在肝脏中代谢活化,生成酰基辅酶A(CoA)和/或酰基葡萄糖醛酸连接的代谢产物,据推测这些代谢产物与免疫原性药物 - 蛋白质加合物的形成有关,因此可能具有肝毒性。在此,我们研究了在悬浮状态下与新鲜分离的大鼠肝细胞孵育时,PAA通过苯乙酰 - S - 酰基 - CoA硫酯(PA - CoA)介导与蛋白质进行共价结合的能力。因此,当肝细胞与羧基 - (14)C标记的苯乙酸(100μM)孵育,并在3小时的时间段内分析PA - CoA的形成以及PAA与蛋白质的共价结合情况时,PA - CoA的形成和与蛋白质的共价结合均迅速增加,孵育4分钟和6分钟后分别达到1.3μM和291 pmol当量/毫克蛋白质。然而,PAA与蛋白质的共价结合是可逆的,在3小时时间点减少了72%。孵育3小时后,PAA主要代谢为苯乙酰甘氨酸酰胺(84%)。在孵育提取物中未检测到PAA - 酰基葡萄糖醛酸。PA - CoA在缓冲液中很容易与谷胱甘肽反应,形成PA - S - 酰基 - 谷胱甘肽;然而,在肝细胞孵育提取物中未检测到这种谷胱甘肽缀合物。肝细胞与月桂酸共同孵育导致PA - CoA形成明显受到抑制,同时相应抑制了与蛋白质的共价结合。SDS - 聚丙烯酰胺凝胶电泳分析显示形成了两种分子量约为29 kDa和约33 kDa的蛋白质加合物。总之,大鼠肝细胞中PA - CoA的形成导致与肝细胞蛋白质的高度选择性但可逆的共价结合,但不会导致谷胱甘肽的转酰化。